{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:17:14Z","timestamp":1788365834987,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcyt.2026.102902","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:03:16Z","timestamp":1777842196000},"page":"102902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Litigating the hype: the Lung Health Institute class action and its implications"],"prefix":"10.1016","volume":"28","author":[{"given":"Mark","family":"Alonzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-6439","authenticated-orcid":false,"given":"Bambi J.","family":"Grilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0993-6713","authenticated-orcid":false,"given":"Laertis","family":"Ikonomou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102902_bib0001","unstructured":"U.S. Department of Justice, Founder and chief executive officer of injectable stem cell product manufacturer sentenced for distributing unapproved drug, 2024. https:\/\/www.justice.gov\/archives\/opa\/pr\/founder-and-chief-executive-officer-injectable-stem-cell-product-manufacturer-sentenced. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0002","unstructured":"Federal Trade Commission, FTC stops deceptive health claims by a stem cell therapy clinic, 2018. https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2018\/10\/ftc-stops-deceptive-health-claims-stem-cell-therapy-clinic. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0003","unstructured":"Federal Trade Commission, Stem cell institute co-founders and companies banned from marketing stem cell treatments and ordered to pay more than $5.1 million for refunds and civil penalties 2025. https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2025\/01\/stem-cell-institute-co-founders-companies-banned-marketing-stem-cell-treatments-ordered-pay-more-51. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0004","unstructured":"Georgia State Office of the Attorney General, Carr, FTC hold companies accountable for deceptive claims regarding stem cell therapy 2021. https:\/\/law.georgia.gov\/press-releases\/2021-08-17\/carr-ftc-hold-companies-accountable-deceptive-claims-regarding-stem-cell. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0005","unstructured":"Nebraska State Office of the Attorney General, Attorney general peterson files lawsuit against stem cell therapy clinic in Omaha, 2020. https:\/\/protectthegoodlife.nebraska.gov\/news\/attorney-general-peterson-files-lawsuit-against-stem-cell-therapy-clinic-omaha. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0006","unstructured":"Iowa State Office of the Attorney General, Attorney general brenna bird secures victory against scam stem cell treatment company, 2025. https:\/\/www.iowaattorneygeneral.gov\/newsroom\/attorney-general-brenna-bird-secures-victory-against-scam-stem-cell-treatment-company. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0007","unstructured":"Washington State Office of the Attorney General, AG Ferguson wins $500,000 for individuals impacted by US stemology\u2019s unproven claims that its stem cell injections could treat COVID-19 and other medical conditions 2022. https:\/\/www.atg.wa.gov\/news\/news-releases\/ag-ferguson-wins-500000-individuals-impacted-us-stemology-s-unproven-claims-its. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0008","unstructured":"New York State Office of the Attorney General, Attorney General James secures $5.1 million judgment against New York City Stem Cell Clinic for scamming patients out of thousands through false advertising, 2021. https:\/\/ag.ny.gov\/press-release\/2021\/attorney-general-james-secures-51-million-judgment-against-new-york-city-stem. (Accessed April 17 2026)."},{"issue":"5","key":"10.1016\/j.jcyt.2026.102902_bib0009","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.stem.2025.04.001","article-title":"Litigation of unlicensed US stem cell products","volume":"32","author":"Lee","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2026.102902_bib0010","unstructured":"Food & Drug Administration, FDA acts to remove unproven, potentially harmful treatment used in \u2018stem cell\u2019 centers targeting vulnerable patients, 2017. https:\/\/wayback.archive-it.org\/7993\/20171114165527\/https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm573427.htm. (Accessed April 17 20206)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0011","unstructured":"Food & Drug Administration, US Stem Cell Clinic, LLC 8\/24\/17, 2017. https:\/\/www.fda.gov\/ICECI\/EnforcementActions\/WarningLetters\/2017\/ucm573187.htm. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0012","unstructured":"Food & Drug Administration, FDA warns StemGenex Biologic Laboratories LLC of illegally marketing an unapproved cellular product manufactured in a facility with significant manufacturing violations, putting patients at risk 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-warns-stemgenex-biologic-laboratories-llc-illegally-marketing-unapproved-cellular-product. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0013","unstructured":"Federal Trade Commission FT, FTC takes aim at deceptive stem cell therapy claims, 2018. https:\/\/www.consumer.ftc.gov\/blog\/2018\/10\/ftc-takes-aim-deceptive-stem-cell-therapy-claims. (Accessed April 17 2026)."},{"issue":"11","key":"10.1016\/j.jcyt.2026.102902_bib0014","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.stem.2021.10.008","article-title":"The American stem cell sell in 2021: US businesses selling unlicensed and unproven stem cell interventions","volume":"28","author":"Turner","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2026.102902_bib0015","unstructured":"Marrero T, Unsatisfied former patient files class-action lawsuit against Lung Institute, 2016. https:\/\/www.tampabay.com\/news\/courts\/civil\/unsatisfied-former-patient-files-class-action-lawsuit-against-lung\/2290989\/. (Accessed April 17 2026)."},{"issue":"11","key":"10.1016\/j.jcyt.2026.102902_bib0016","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJMoa1609583","article-title":"Vision loss after intravitreal injection of autologous \"Stem Cells\" for AMD","volume":"376","author":"Kuriyan","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jcyt.2026.102902_bib0017","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2019.14703","article-title":"Pay-to-participate trials and vulnerabilities in research ethics oversight","volume":"322","author":"Lynch","year":"2019","journal-title":"JAMA-J Am Med Assoc"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102902_bib0018","first-page":"479-+","article-title":"The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies","volume":"66","author":"von Tigerstrom","year":"2011","journal-title":"Food Drug Law J"},{"key":"10.1016\/j.jcyt.2026.102902_bib0019","unstructured":"Hiltzik M, A win for the FDA\u2019s campaign against bogus stem cell treatments, 2024. https:\/\/www.latimes.com\/business\/story\/2024-09-27\/hiltzik-column-a-federal-appeals-court-hands-the-fda-a-stupendous-win-in-its-battle-against-stem-cell-clinics. (Accessed April 17 2026)."},{"issue":"5","key":"10.1016\/j.jcyt.2026.102902_bib0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.molmed.2015.02.008","article-title":"US stem cell clinics, patient safety, and the FDA","volume":"21","author":"Turner","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jcyt.2026.102902_bib0021","unstructured":"Wan W, McGinley L, Clinic pitches unproven treatments to desperate patients, with tips on raising the cash, 2019. https:\/\/www.washingtonpost.com\/national\/health-science\/clinic-pitches-unproven-treatments-to-desperate-patients-with-tips-on-raising-the-cash\/2019\/12\/01\/fe94cfcc-d3c6-11e8-8c22-fa2ef74bd6d6_story.html. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0022","unstructured":"LaGrone K, Lung institute in Tampa guilty of selling patients \u201cvalueless\u201d treatments for incurable lung disease, 2024. https:\/\/www.tampabay28.com\/news\/state\/lung-institute-in-tampa-guilty-of-selling-patients-valueless-treatments-for-incurable-lung-disease. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0023","unstructured":"Outten J, FDA warns patients of stem cell scams, 2012. https:\/\/www.theregreview.org\/2012\/02\/03\/fda-warns-patients-of-stem-cell-scams\/. (Accessed April 17 2026)."},{"key":"10.1016\/j.jcyt.2026.102902_bib0024","unstructured":"Silva L, StemGenex, lead doctor to pay $3.65M for fraudulent stem cell therapy scheme, 2022. https:\/\/topclassactions.com\/lawsuit-settlements\/medical-problems\/medical-malpractice\/stemgenex-lead-doctor-to-pay-3-65m-for-fraudulent-stem-cell-therapy-scheme\/. (Accessed April 17 2026)."},{"issue":"2","key":"10.1016\/j.jcyt.2026.102902_bib0025","first-page":"311","article-title":"Combatting unlicensed stem cell interventions through truthful advertising law: a survey of regulatory trends","volume":"9","author":"Ogbogu","year":"2016","journal-title":"McGill J Law Health"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102902_bib0026","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jcyt.2017.10.002","article-title":"Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions","volume":"20","author":"Weiss","year":"2018","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102902_bib0027","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.stemcr.2021.05.012","article-title":"ISSCR Guidelines for stem cell research and clinical translation: The 2021 update","volume":"16","author":"Lovell-Badge","year":"2021","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.jcyt.2026.102902_bib0028","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41536-018-0043-6","article-title":"Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions","volume":"3","author":"Horner","year":"2018","journal-title":"npj Regen Med"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102902_bib0029","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.stemcr.2021.10.007","article-title":"Weighing up the evidence used by direct-to-consumer stem cell businesses","volume":"16","author":"Cook","year":"2021","journal-title":"Stem Cell Rep"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102902_bib0030","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jcyt.2023.03.002","article-title":"Gene ICEC. International Society for Cell & Gene Therapy Position Paper: key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products","volume":"25","author":"Ikonomou","year":"2023","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102902_bib0031","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13287-021-02254-4","article-title":"Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study","volume":"12","author":"Chavez","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102902_bib0032","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/rme-2021-0070","article-title":"Online seminars as an information source for direct-to-consumer stem cell therapy","volume":"17","author":"Hassoun","year":"2022","journal-title":"Regen Med"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102902_bib0033","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.stemcr.2019.05.009","article-title":"How to peddle hope: an analysis of YouTube patient testimonials of unproven stem cell treatments","volume":"12","author":"Hawke","year":"2019","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.jcyt.2026.102902_bib0034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41536-017-0036-x","article-title":"The malignant niche: safe spaces for toxic stem cell marketing","volume":"2","author":"Sipp","year":"2017","journal-title":"npj Regen Med"},{"key":"10.1016\/j.jcyt.2026.102902_bib0035","unstructured":"ISCT, ISCT files amicus brief supporting FDA's authority to regulate unproven stem cell-based interventions 2023. https:\/\/www.isctglobal.org\/telegrafthub\/blogs\/lauren-reville\/2023\/06\/14\/isct-files-amicus-brief-supporting-fdas-authority. (Accessed April 17 2026)."},{"issue":"10","key":"10.1016\/j.jcyt.2026.102902_bib0036","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.stem.2024.09.007","article-title":"Effective regulatory responses to predatory stem cell markets in Australia and Canada","volume":"31","author":"Ikonomou","year":"2024","journal-title":"Cell Stem Cell"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:24:30Z","timestamp":1788362670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926008637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1465324926008637"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102902","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Litigating the hype: the Lung Health Institute class action and its implications","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102902","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102902"}}